2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM: Abstract Number: 2656

Alterations of the Splicing Machinery Components in Leukocytes from Systemic Lupus Erythematosus Patients Influences Its Development and Atherothrombotic Profile and Drives the Therapeutic Response

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2426

Altered Frequencies of Circulating Follicullar T Helper Cell Counterparts and Their Subsets but Not of Peripheral Helper T Cells, Are Associated with Increased Circulating Plasmablasts in Seropositive Early RA Patients

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2006

Altered Microcirculation As a Proxy for Inflammation in Hand Osteoarthritis Can Reliably be Assessed Using Fluorescence Optical Imaging

Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2403

Amylin in the Insulin Resistance of Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 1956

An Approach to Linkage of Registry Data to Medicare Claims Using Multiple Non-Unique Identifiers

Epidemiology and Public Health Poster III: Rheumatic Disease Risk and Outcomes

9:00AM-11:00AM: Abstract Number: 2196

An Exploratory Analysis of Physical Activity Levels and the Presence of Bone Marrow Lesions in Adults with Knee Osteoarthritis: Data from the Osteoarthritis Initiative

Osteoarthritis – Clinical Aspects Poster II: Observational and Epidemiological Studies

9:00AM-11:00AM: Abstract Number: 2100

An International Consensus Exercise to Develop Candidate Items for Classification Criteria in Relapsing Polychondritis

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2273

An Open-Label Extension Study to Assess the Long-Term Safety of Etanercept in Pediatric Patients with Extended Oligo, Enthesitis Related, and Psoriatic Juvenile Idiopathic Arthritis: 6-Year Data from the Clipper Studies

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

9:00AM-11:00AM: Abstract Number: 2224

Analgesic Potential of NEO6860, a Modality Selective TRPV1 Antagonist, in Osteoarthritis Knee Pain: Results of a Randomized, Controlled, Proof-of-Concept Trial

Pain – Basic and Clinical Aspects Poster

9:00AM-11:00AM: Abstract Number: 2650

Analysis of C9Orf72 Expansions in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Data

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2050

Analysis of Data Collected from Right and Left Limbs: Accounting for Dependence and Improving Statistical Efficiency in Musculoskeletal Research

ARHP Measures and Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Abstract Number: 1995

Analysis of Erosion Volume of the Distal Radius By HR-pQCT in Patients with Rheumatoid Arthritis

Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2680

Analysis of Prognostic Determinants of Scleroderma-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2139

Analysis of Required Dose of Corticosteroid As Maintenance Therapy and Related Factors in Patients with Polymyositis/Dermatomyositis

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2494

Analysis of the Efficacy, Safety and Continuation Rate of Abatacept in Elderly Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].